Xintela AB (publ) (STO:XINT)
0.2520
-0.0070 (-2.70%)
May 21, 2026, 12:21 PM CET
Xintela AB Revenue
In the year 2025, Xintela AB had annual revenue of 2.28M SEK, down -45.86%. Xintela AB had revenue of 415.00K in the quarter ending December 31, 2025, a decrease of -61.93%.
Revenue
2.28M
Revenue Growth
-45.86%
P/S Ratio
97.75
Revenue / Employee
175.54K
Employees
13
Market Cap
223.07M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.28M | -1.93M | -45.86% |
| Dec 31, 2024 | 4.22M | 4.14M | 5,303.85% |
| Dec 31, 2023 | 78.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xbrane Biopharma AB | 76.45M |
| Nanologica AB | 21.13M |
| Elicera Therapeutics AB | 10.64M |
| Simris Group AB (PUBL) | 2.65M |
| Alligator Bioscience AB | 520.00K |
| Diamyd Medical AB | 362.00K |
| Mendus AB | -1.44M |
Xintela AB News
- 8 months ago - Xintela AB Transcript: Investing in Life Science 2025 - Transcripts